SCHEMBL2804114

SCHEMBL2804114

O=C(NCc1ccc(Cl)cc1)c1cccc(NC(=O)N2CCc3c(cnc4[nH]ncc34)C2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.47
PAK1 Q13153 1/20 0.45
KMT2A Q03164 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
MAPK1 P28482 1/20 0.42
PDGFRB P09619 2/20 0.42
KDR P35968 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NLRP3 Q96P20 1/20 0.42
CXCR3 P49682 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
CLK4 Q9HAZ1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802876 0.93 PAK1 (0.48) NAMPTPAK1NPC1RAB9ACASP3
SCHEMBL2486603 0.93 TP53 (0.47) NAMPTNPC1RAB9AMAPK1PDGFRB
SCHEMBL2803726 0.91 NAMPT (0.50) NAMPTNPC1RAB9APDGFRBKDR
SCHEMBL2804050 0.90 NAMPT (0.52) NAMPTPAK1NPC1RAB9AMAPK1
SCHEMBL2483910 0.88 NAMPT (0.51) NAMPTPDGFRBKDRSMN1; SMN2LMNA
SCHEMBL2802581 0.88 NAMPT (0.55) NAMPTPAK1KMT2ANPC1RAB9A
SCHEMBL2483703 0.87 NPC1 (0.46) NAMPTPAK1KMT2ANPC1RAB9A
SCHEMBL2490140 0.86 NAMPT (0.53) NAMPTKMT2ANPC1RAB9APDGFRB
SCHEMBL2804019 0.85 NAMPT (0.50) NAMPTNPC1RAB9APDGFRBKDR
SCHEMBL2804475 0.85 TP53 (0.46) NAMPTPAK1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 NAMPT 212/4885PAK1 717/4885KMT2A 1795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.